TH103

July 17, 2026: Kalaris Therapeutics, Inc. (NASDAQ: KLRS) reported positive additional data from its Phase 1a single-ascending dose (SAD) trial of TH103 in neovascular age-related macular degeneration (AMD), with updated results presented at the American Society of Retina Specialists (ASRS) Annual Meeting (8:00 am EDT).

The expanded SAD dataset included 17 treatment-naïve patients plus 3 treatment-experienced patients in a safety cohort; all 20 completed six months of follow-up. In the efficacy analysis (treatment-naïve patients), Kalaris said findings continued to show structural and functional improvements, supporting potential extended durability. Pharmacokinetic results showed 27- to 53-fold lower plasma Cmax (molar equivalence basis) versus leading anti-VEGF agents, suggesting greater intraocular retention. After a single injection, 41% of treatment-naïve patients had first retreatment at ≥4 months, 35% at ≥5 months, and 29% required no additional anti-VEGF treatment through six months; treatment-experienced patients (N=3) had an average 2-month extension versus prior intervals.

Safety: no intraocular inflammation (IOI) among six patients at 2.5 mg using product made after impurity-reducing process adjustments; one transient IOI case previously reported at 5 mg resolved without sequelae.

The ongoing Phase 1b/2 multiple-ascending dose study (standard four-dose loading regimen) is enrolling; initial data are expected in 1H 2027 to inform dose selection for potential Phase 3 trials.